Protection against infectious
laryngotracheitis powered by VAXXITEK®
The
POWER to
PROTECT
uniquely and conveniently
A strong immune foundation and optimized protection against Marek's diease, infectious bursal disease, and infectious laryngotracheitis in one shot.
PROTECT FLOCKS IN THE HATCHERY WITH A 3-IN-1 SOLUTION
3 in 1
Building on the trusted vaccination platform used to develop VAXXITEK® HVT+IBD, our research and manufacturing experts successfully designed a 3-in-1 vaccine that provides a strong immune foundation and optimizes protection against Marek’s disease (MD), infectious bursal disease (IBD)—and infectious laryngotracheitis (ILT).
It all starts with the same bioengineering platform as the original Vaxxitek® HVT+IBD in order to capture it's recognized benefits. Next, the immunogenic glycoprotein D ILT is inserted for optimal ILT protection. This unique vector vaccine has a single promoter for 2 disease inserts (IBD and ILT), which leads to consistent antigen expression and immunity.1
🗎 Download SDS
🗎 Download Sales Aid
▹ Watch VAXXITEK® HVT+IBD+ILT Video
▹ Watch Technical Video
Boehringer Ingelheim Animal Health Canada Inc.
Poultry Business Unit
5180 S Service Rd. Burlington, ON L7L 5H4
Customer Care: 1-800-567-1885
References: 1. Data on file. Boehringer Ingelheim Animal Health. 2. Morton DB. Vaccines and animal welfare. Rev Sci Tech. 2007;26:157–163. 3. Lemiere S, Rojo F, Fernandez R, et al. Benefits of the herpesvirus of turkey vector vaccine of infectious bursal disease in control of immuno-depression in broilers and decrease of use of antibiotic medication. In: Proceedings from the XVIII Congress of the World Veterinary Poultry Association Congress; August 19–23, 2013; Nantes, France. Abstract. 4. Hoelzer K, Bielke L, Blake DP, et al. Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions. Vet Res. 2018;49:70. 5. Atienza JC, Nagera AJ, Martinez PO, et al. Evaluation of a herpesvirus of turkey vector vaccine inducing protection against infectious bursal and Marek’s diseases (VAXXITEK® HVT + IBD) under Philippines field conditions. In: Proceedings from the XXIII World’s Poultry Congress; June 29–July 4, 2008; Queensland, Australia. 6. Rautenschlein S, Lemiere S, Simon B, Prandini F. A comparison of the effects of the humoral and cell-mediated immunity between an HVT-IBD vector vaccine and an IBDV-immune complex vaccine after in ovo vaccination of commercial broilers. In: Proceedings from the XVII Congress of the World Veterinary Poultry Association Congress; August 14–18, 2011; Cancun, Mexico: 830–843. 7. Tang SF, He SJ, Li WM, Lemiere S. Field experience of vaccination in day-old broiler chickens with a herpesvirus turkey-infectious bursal disease (HVT-IBD) vector vaccine in different systems of chicken production across China. Poster presentation. In: Proceedings from the XVII Congress of the World Veterinary Poultry Association Congress; August 14–18, 2011; Cancun, Mexico: 920–926. 8. Zhou X, Wang D, Xiong J, Zhang P, Li Y, She R. Protection of chickens, with or without maternal antibodies, against IBDV infection by a recombinant IBDV-VP2 protein. Vaccine. 2010;28:3990–3996. 9. Merial Select, Inc., 2017. Report number 16-187. 10. Boehringer Ingelheim R&D, 2017. Report number 17.0107.R.